Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al.'s Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e51-2.  [electronic resource] 

 -  European urology  03 2019 
 - e53 p.  digital 
<br/><br/> Publication Type: Letter; Comment 
<br/><br/><label>ISSN: </label>1873-7560 
<br/><br/><label>Standard No.: </label>10.1016/j.eururo.2018.11.053  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abiraterone Acetate<br/>Humans<br/>Male<br/>Neoplasms, Second Primary<br/>Prostatic Neoplasms<br/>Prostatic Neoplasms, Castration-Resistant<br/>Radium